Ready to Jump After Recent Trade: Pacific Biosciences of California Inc (PACB)

With 11.08 million shares changed hands, the volume of the stock remained lighter than its average volume of 11.09 million shares. The 52-week range on PACB shows that it touched its highest point at $6.09 and its lowest point at $1.16 during that stretch. It currently has a 1-year price target of $2.54. Beta for the stock currently stands at 1.84.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PACB was down-trending over the past week, with a drop of -16.58%, but this was down by -7.69% over a month. Three-month performance dropped to -9.30% while six-month performance rose 8.33%. The stock lost -69.59% in the past year, while it has lost -14.75% so far this year. A look at the trailing 12-month EPS for PACB yields -1.14 with Next year EPS estimates of -0.61. For the next quarter, that number is -0.19. This implies an EPS growth rate of 33.82% for this year and 17.90% for next year. EPS is expected to grow by 24.02% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -15.31%.

Float and Shares Shorts:

At present, 273.86 million PACB shares are outstanding with a float of 243.51 million shares on hand for trading.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for PACB since 11 analysts follow the stock currently. There are 6 analysts who recommend BUY ratings, while 1 suggest SELL ratings. Of the remaining analysts, 4 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$1.17512 being high and -$1.94862 being low. For PACB, this leads to a yearly average estimate of -$1.35362. Based on analyst estimates, the high estimate for the next quarter is -$0.16 and the low estimate is -$0.21. The average estimate for the next quarter is thus -$0.19.